New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 23, 2014
07:53 EDTAMGNAmgen weakness a buying opportunity, says Cowen
Cowen would use any weakness in Amgen as buying opportunity and said the recent shortfall was due to seasonal factors and that 2014 remains on track. The firm cited company guidance, its superior profile relative to peers, potential for increased dividends, and a maturing pipeline. Shares are Outperform rated with a $131 price target.
News For AMGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 31, 2015
09:25 EDTAMGNOn The Fly: Pre-market Movers
Subscribe for More Information
08:52 EDTAMGNAmgen results highlight Ligand royalty strength, says Roth Capital
Roth Capital notes Amgen (AMGN) reported Q2 Kyprolis sales of $119M compared to its estimate of $117M. The drug, alongside Promacta, represent the majority of Ligand's current royalty stream, the firm tells investors. It believes the growth of Kyprolis highlights Ligand's "strong core royalty bearing asset lineup." Roth keeps a Buy rating on the stock with a $135 price target.
July 30, 2015
19:35 EDTAMGNOn The Fly: After Hours Movers
UP AFTER EARNINGS: YRC Worldwide (YRCW), up 17.7%... SkyWest (SKYW), up 11.5%... Zeltiq Aesthetics (ZLTQ), up 9%... Columbia Sportswear (COLM), up 11%... Expedia (EXPE), up 7.9%... Ellie Mae (ELLI), up 7%... Comfort Systems (FIX), up 6.2%... DigitalGlobe (DGI), up 5%... Fiesta Restaurant Group (FRGI), up 8%... Amgen (AMGN), up 1.9%. ALSO HIGHER: Juno Therapeutics (JUNO), up 1.7% after getting FDA clearance for IND application for JCAR015... Priceline (PCLN), up 1.5% following Expedia's quarterly results... Coca-Cola Enterprises (CCE), up 9.6% after the Wall Street Journal reported that the company is in advanced talks with Coca-Cola bottlers... Endurance Specialty (ENH), up 2.6% after being added to the S&P MidCap 400. DOWN AFTER EARNINGS: Oculus (OCLS), down 17%... Computer Programs (CPSI), down 11.9%... Outerwall (OUTR), down 9.2%... FireEye (FEYE), down 5.2% after reporting quarterly results and that CFO Michael Sheridan intends to leave the company... Hanesbrands (HBI), down 8.5%... Solazyme (SZYM), down 8.8%... Boston Beer (SAM), down 5.2%... Ocwen Financial (OCN), down 10.7%... LinkedIn (LNKD), down 4.5%... Electronic Arts (EA), down 3.2%.
19:31 EDTAMGNAmgen price target raised to $200 from $192 at Piper Jaffray
Piper Jaffray analyst Joshua Schimmer raised his price target for Amgen shares to $200 after the company reported Q2 results after the close. Amgen kept its track record of beating consensus and raising original 2015 guidance, Schimmer tells investors in a research note. He reiterates an Overweight rating on the name. Shares of Amgen are up $3.61 to $175.30 in after-hours trading.
16:05 EDTAMGNAmgen raises FY15 adjusted EPS outlook to $9.55-$9.80 from $9.35-$9.65
Consensus $9.62. Raises FY15 revenue outlook to $21.1B-$21.4B from $20.9B-$21.3B, consensus $21.17B.
16:04 EDTAMGNAmgen reports Q2 adjusted EPS $2.57, consensus $2.43
Reports Q2 revenue $5.37B, consensus $5.32B.
15:04 EDTAMGNNotable companies reporting after market close
Subscribe for More Information
13:14 EDTAMGNAmgen technical notes ahead of earnings
Subscribe for More Information
12:37 EDTAMGNAmgen July weekly 172.5 straddle priced for 3.7% movement into Q2
Subscribe for More Information
12:05 EDTAMGNEarnings Watch: Amgen shares up about 1.5% since last report
Subscribe for More Information
July 29, 2015
07:49 EDTAMGNAmgen July weekly volatility elevated into Q2 and outlook
Amgen July weekly call option implied volatility is at 61, August is at 32, September is at 29; compared to its 52-week range of 18 to 34, suggesting large near term price movement into the expected release of Q2 results on July 30.
05:59 EDTAMGNStocks with implied volatility movement; AMGN CLF
Stocks with implied volatility movement; Amgen (AMGN) 30, Cliffs Natural (CLF) 125 according to iVolatility.
July 28, 2015
07:34 EDTAMGNJefferies sees entry point for Aegerion, upgrades to Buy
Subscribe for More Information
July 24, 2015
15:00 EDTAMGNBroader label for PCSK9 drug positive for Regeneron, Amgen, says Deutsche Bank
Subscribe for More Information
12:44 EDTAMGNAmgen announces FDA approval of expanded Kyprolis indication
Subscribe for More Information
12:27 EDTAMGNFDA approves expanded use of Kyprolis in multiple myeloma patients
The FDA announced that on July 24 the administration approved carfilzomib, or Kyprolis, marketed by Onyx Pharmaceuticals, an Amgen (AMGN) subsidiary, in combination with lenalidomide and dexamethasone for the treatment of patients with relapsed multiple myeloma who have received one to three prior lines of therapy. The revised labeling includes new Warnings and Precautions for VTE, cardiac toxicities, acute renal failure, pulmonary toxicities, and hypertension. The increased safety risks, including mortality, for elderly patients is described. Detailed safety information in the prescribing information was also updated for use of carfilzomib monotherapy. Reference Link
July 23, 2015
09:10 EDTAMGNAmgen submits NDA for Kyprolis in relapsed multiple myeloma
Amgen submitted a supplemental New Drug Application to the FDA for Kyprolis for Injection to seek an expanded indication for the treatment of patients with a form of blood cancer, relapsed multiple myeloma, who have received at least one prior therapy. Kyprolis currently has accelerated approval in the U.S. for the treatment of patients with relapsed multiple myeloma as a monotherapy. The sNDA is based on data from the global Phase 3 ENDEAVOR trial in which relapsed multiple myeloma patients treated with Kyprolis and dexamethasone lived twice as long without their disease worsening, demonstrating statistically and clinically significant superiority over Velcade.
July 21, 2015
12:47 EDTAMGNPiper confident in Regeneron approval by Friday
After Amgen's (AMGN) Repatha received marketing authorization in Europe, making it the first of the anti-PCSK9 antibody to be approved worldwide, Piper Jaffray analyst Edward Tenthoff expressed confidence that Regeneron (REGN) and Sanofi's (SNY) anti-PCSK9 antibody Praluent will be approved by Friday's FDA action date. Tenthoff believes Praluent will eventually be a blockbuster drug, but anticipates the launch to be slow. He keeps a Neutral rating on Regeneron with a $484 price target.
11:49 EDTAMGNNovartis may sell Amgen's cancer drug as soon as September, Bloomberg says
Subscribe for More Information
07:12 EDTAMGNAmgen's Repatha granted marketing authorization by EC
Amgen announced that the European Commission, or EC, has granted marketing authorization for Repatha, or evolocumab, the first proprotein convertase subtilisin/kexin type 9, or PCSK9, inhibitor to be approved in the world, for the treatment of patients with uncontrolled cholesterol who require additional intensive low-density lipoprotein cholesterol reduction. Repatha is a human monoclonal antibody that inhibits PCSK9, a protein that reduces the liver's ability to remove LDL-C, or "bad" cholesterol, from the blood.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use